It’s not AbbVie’s first foray into T-cell engager dealmaking—the pharma paid $65 million upfront in October to license EvolveImmune’s multispecific biologics for various targets in solid ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Normunity Inc. has closed a $75 million series B financing to support its pipeline of novel anticancer therapies targeting untapped drug mechanisms. Proceeds from the financing will be used to advance ...